HKSE:01099 (China)
Business Description
Sinopharm Group Co Ltd
NAICS : 325412
No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Compare
Compare
Traded in other countries / regions
X2S.Germany
•
01099.Hong Kong
•
SHTDF.USA
Description
Sinopharm Group was founded in 2003 and listed on the Hong Kong Stock Exchange in September 2009. Its main business is drug distribution in mainland China, which contributes about 76% of total revenue. It is the largest drug distributor, with approximately 20% market share. Other notable segments are medical device distribution, which contributes about 20% of revenue, and retail pharmacies, which contributes about 5%. These are fast-growing industries, where government policy is designed to encourage consolidation and promote large players with scale and efficiency advantages.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.64 | |||||
| Equity-to-Asset | 0.19 | |||||
| Debt-to-Equity | 1.11 | |||||
| Debt-to-EBITDA | 2.79 | |||||
| Interest Coverage | 5.71 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.12 | |||||
| Beneish M-Score | -2.3 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.8 | |||||
| 3-Year EBITDA Growth Rate | 15 | |||||
| 3-Year EPS without NRI Growth Rate | 11.1 | |||||
| 3-Year FCF Growth Rate | 207.7 | |||||
| 3-Year Book Growth Rate | 14 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | -8.84 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 7.75 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 17.77 | |||||
| 9-Day RSI | 25.95 | |||||
| 14-Day RSI | 31.12 | |||||
| 6-1 Month Momentum % | -2.41 | |||||
| 12-1 Month Momentum % | -14.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.33 | |||||
| Quick Ratio | 1.09 | |||||
| Cash Ratio | 0.2 | |||||
| Days Inventory | 37.79 | |||||
| Days Sales Outstanding | 111.73 | |||||
| Days Payable | 93.85 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 5.15 | |||||
| Dividend Payout Ratio | 0.28 | |||||
| 3-Year Dividend Growth Rate | 9.1 | |||||
| Forward Dividend Yield % | 5.15 | |||||
| 5-Year Yield-on-Cost % | 8.64 | |||||
| 3-Year Average Share Buyback Ratio | -1.6 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 8.46 | |||||
| Operating Margin % | 4.12 | |||||
| Net Margin % | 1.49 | |||||
| ROE % | 13.34 | |||||
| ROA % | 2.37 | |||||
| ROIC % | 10.73 | |||||
| ROC (Joel Greenblatt) % | 19.96 | |||||
| ROCE % | 18.73 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 5.45 | |||||
| Forward PE Ratio | 6.38 | |||||
| PE Ratio without NRI | 5.55 | |||||
| Shiller PE Ratio | 8.01 | |||||
| PEG Ratio | 0.39 | |||||
| PS Ratio | 0.08 | |||||
| PB Ratio | 0.68 | |||||
| Price-to-Tangible-Book | 0.86 | |||||
| Price-to-Free-Cash-Flow | 5.65 | |||||
| Price-to-Operating-Cash-Flow | 4.34 | |||||
| EV-to-EBIT | 3.26 | |||||
| EV-to-Forward-EBIT | 3.91 | |||||
| EV-to-EBITDA | 2.76 | |||||
| EV-to-Forward-EBITDA | 3.4 | |||||
| EV-to-Revenue | 0.13 | |||||
| EV-to-Forward-Revenue | 0.13 | |||||
| EV-to-FCF | 9.13 | |||||
| Price-to-Projected-FCF | 0.27 | |||||
| Price-to-DCF (Earnings Based) | 0.23 | |||||
| Price-to-DCF (FCF Based) | 0.42 | |||||
| Price-to-Median-PS-Value | 0.27 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.39 | |||||
| Price-to-Graham-Number | 0.46 | |||||
| Price-to-Net-Current-Asset-Value | 2.46 | |||||
| Earnings Yield (Greenblatt) % | 30.59 | |||||
| Forward Rate of Return (Yacktman) % | 29.88 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 633,919.512 | ||
| EPS (TTM) (HK$) | 3.03 | ||
| Beta | 1.31 | ||
| Volatility % | 19.52 | ||
| 14-Day RSI | 31.12 | ||
| 14-Day ATR (HK$) | 0.488716 | ||
| 20-Day SMA (HK$) | 17.753 | ||
| 12-1 Month Momentum % | -14.21 | ||
| 52-Week Range (HK$) | 16.22 - 22.5 | ||
| Shares Outstanding (Mil) | 3,120.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sinopharm Group Co Ltd Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||